Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde

Carcinogenesis

Volumn 19, Issue 7, 1998, Pages 1275-1283

  Ji, Chuan ^a   Rouzer, Carol A ^b   Marnett, Lawrence J ^a   Pietenpol, Jennifer A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTERN MARYLAND COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALONALDEHYDE; PROTEIN P21; PROTEIN P53; REGULATOR PROTEIN;

ARTICLE; CELL CYCLE; CELL KINETICS; COLORECTAL CARCINOMA; DNA ADDUCT; GENOTOXICITY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; LUNG ADENOCARCINOMA; MITOSIS INHIBITION; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, LARGE CELL; CELL CYCLE; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASES; DNA DAMAGE; DOXORUBICIN; HUMANS; LIPID PEROXIDATION; LUNG NEOPLASMS; MALONDIALDEHYDE; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031878858     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/19.7.1275     Document Type: Article

References (64)

1. Janero, D.R. (1990) Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Rad. Biol. Med., 9, 515-540.
2. Mukai, F.H. and Goldstein, B.D. (1976) Mutagenicity of malondialdehyde, a decomposition product of peroxidized polyunsaturated fatty acids. Science, 191, 868-869.
3. Basu, A.K. and Marnett, L.J. (1983) Unequivocal demonstration that malondialdehyde is a mutagen. Carcinogenesis, 4, 331-333.
4. Yau, T.M. (1979) Mutagenicity and cytotoxicity of malondialdehyde in mammalian cells. Mech. Aging Dev., 11, 137-144.
5. Spalding, J.W. (1988) Toxicology and carcinogenesis studies of malondialdehyde sodium salt (3-hydroxy-2-propenal, sodium salt) in F344/ N rats and B6C3F1 mice. NTP Tech. Rep., 331, 5-13.
6. Seto, H., Seto, T., Takesue, T. and Ikemura, T. (1983) Reaction of malondialdehyde with nucleic acid. I. Formation of fluorescent pyrimidol {1,2-a}purin-10(3H)-one nucleosides. Bull. Chem. Soc. Jpn, 56, 1799-1802.
7. Seto, H., Seto, T., Takesue, T. and Ikemura, T. (1986) Reaction of malondialdehyde with nucleic acid. III. Studies of the fluorescent substances released by enzymatic digestion of nucleic acids modified with malondialdehyde. Chem. Pharm. Bull., 34, 5079-5085.
8. Nair, V., Turner, G.A. and Offerman, R.J. (1984) Novel adducts from the modification of nucleic acid bases of malondialdehyde. J. Am. Chem. Soc., 106, 3370-3371.
9. Basu, A.K., O'Hara, S.M., Valladier, P., Stone, K., Mols, O. and Marnett, L.J. (1988) Identification of adducts formed by reaction of guanine nucleosides and malondialdehyde and structurally related aldehydes. Chem. Res. Toxicol., 1, 53-59.
10. Stone, K., Ksebati, M. and Marnett, L.J. (1990) Investigation of the adducts formed by reaction of malondialdehyde and adenosine. Chem. Res. Toxicol., 3, 33-38.
11. Stone, K., Uzieblo, A. and Marnett, L.J. (1990) Studies of the reaction of malondialdehyde with cytosine nucleosides. Chem. Res. Toxicol., 3, 467-472.
12. Chaudhary, A.K., Nokubo, M., Reddy, G.R., Yeola, S.N., Morrow, J.D., Blair, I.A. and Marnett, L.J. (1994) Detection of endogenous malondialdehyde-deoxyguanosine adducts in human liver. Science, 265, 1580-1582.
13. Fink, S.P., Reddy, G.R. and Marnett, L.J. (1997) Mutagenicity in Escherichia coli of the major DNA adduct derived from the endogenous mutagen malondialdehyde. Proc. Natl Acad. Sci. USA, 94, 8652-8657.
14. Hartwell, L.H. and Weinert, T.A. (1989) Checkpoints: Controls that ensure the order of cell cycle events. Science, 246, 629-634.
15. Rouzer, C.A., Chaudhary, A.K., Nokubo, M., Ferguson, D.M., Reddy, G.R., Blair, I.A. and Marnett, L.J. (1997) Analysis of the malondialdehyde-2′-deoxyguanosine adduct, pyrimidopurinone, in human leukocyte DNA by gas chromatography/electron capture negative chemical ionization/mass spectrometry. Chem. Res. Toxicol., 10, 181-188.
16. Sevilla, C.L., Mahle, N.H., Eliezer, N., Uzieblo, A., O'Hara, S.M., Nokubo, M., Rouzer, C.A. and Marnett, L.J. (1997) Development of monoclonal antibodies to the malondialdehyde-deoxyguanosine adduct, pyrimidopurinone. Chem. Res. Toxicol., 10, 172-180.
17. Mitsudomi, T., Steinberg, S.M., Nau, M.M., et al. (1992) p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7, 171-180.
18. 1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
19. Arcamone, F. (1985) Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture. Cancer Res., 45, 5995-5999.
20. El-Deiry, W.S., Tokino, T., Velculescu, V.E., et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
21. Macleod, K.F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B. and Jacks, T. (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9, 935-944.
22. Akashi, M., Hachiya, M., Osawa, Y., Spirin, K., Suzuki, G. and Koeffler, H.P. (1995) Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. J. Biol. Chem., 270, 19181-19187.
23. Osawa, Y., Hachiya, M., Koeffler, H.P., Suzuki, G. and Akashi, M. (1995) IL-1 induces expression of WAF1 mRNA in human fibroblasts: Mechanisms of accumulation. Biochem. Biophys. Res. Commun., 216, 429-437.
24. cdc2 protein kinase during mitosis. Cell, 58, 361-372.
25. Nurse, P. (1990) Universal control mechanism regulating onset of M-phase. Nature, 344, 503-508.
26. Roberts, J.M., Koff, A., Polyak, K., Firpo, E., Collins, S., Ohtsubo, M. and Massagué, J. (1994) Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harbor Symp. Quant. Biol., 59, 31-38.
27. 1-to-S phase transition. Mol. Cell. Biol., 15, 2612-2624.
28. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol., 14, 1669-1679.
29. Koff, A., Giordano, A., Desai, D., et al. (1992) Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science, 257, 1689-1694.
30. Gu, Y., Turck, C.W. and Morgan, D.O. (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature, 366, 707-710.
31. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. and Elledge, S.J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
32. Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
33. Xiong, Y., Zhang, H. and Beach, D. (1993) Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev., 7, 1572-1583.
34. Poon, R.Y.C., Jiang, W., Toyoshima, H. and Hunter, T. (1996) Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/ Tyr-15 phosphorylation after UV-induced DNA damage. J. Biol. Chem., 271, 13283-13291.
35. Gould, K.L. and Nurse, P. (1989) Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis. Nature, 342, 39-45.
36. Lundgren, K., Walworth, N., Booher, R. Dembski, M., Kirschner, M. and Beach, D. (1991) mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Science, 270, 86-90.
37. Mueller, P.R., Coleman, T.R., Kumagai, A. and Dunphy, A. (1995) Myt1: a membrane-associated inhibitory kinase that phosphorylates cdc2 on both threonine-14 and tyrosine-15. Science, 270, 86-93.
38. Liu, F., Stanton, J.J., Wu, Z. and Piwnica-Worms, H. (1997) The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol. Cell. Biol., 17, 571-583.
39. Galaktionov, K. and Beach, D. (1991) Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cyclins. Cell, 67, 1181-1194.
40. Hartwell, L.H. and Kastan, M.B. (1994) Cell cycle control and cancer. Science, 266, 1821-1828.
41. Russo, T., Zambrano, N., Esposito, F., et al. (1995) A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem., 270, 29386-29391.
42. Ji, C., Marnett, L.J. and Pietenpol, J.A. (1997) Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated levels of p53 and p21 protein levels. Oncogene, 15, 2749-2753.
43. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82, 675-684.
44. Brugarolas, J., Chandrasekaran, C., Gordon, J.I., Beach, D., Jacks, T. and Hannon, G.J. (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature, 377, 552-557.
45. Waga, S., Hannon, G.J., Beach, D. and Stillman, B. (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574-578.
46. Flores-Rozas, H., Kelman, Z., Dean, F.B., Pan, Z.Q., Harper, J.W., Elledge, S.J., O'Donnell, M. and Hurwitz, J. (1994) Cdk-interacting protein 1 binds proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl Acad. Sci. USA, 91, 8655-8659.
47. Chen, J., Jackson, P.K., Kirschner, M.W. and Dutta, A. (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature, 374, 386-388.
48. Cip1. Nature, 375, 159-161.
49. WAF1 and proliferating cell nuclear antigen. Curr. Biol., 5, 275-282.
50. Li, R., Waga, S., Hannon, G.J., Beach, D. and Stillman, B. (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature, 371, 534-537.
51. WAF1/CIP1-/- human cancer cells. Cancer Res., 56, 2250-2255.
52. 2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J. Biol. Chem., 268, 8298-8308.
53. McKenna, W.G., Iliakis, G., Weiss, M.C., Bernhard, E.J. and Muschel, R.J. (1991) Increased G2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc. Radiat. Res., 125, 283-287.
54. 2 arrest in Chinese hamster ovary cells. Cancer Res., 50, 3761-3766.
55. cdc2. Cancer Res., 54, 1412-1414.
56. Maity, A., McKenna, W.G. and Muschel, R.J. (1995) Evidence for post-transcriptional regulation of cyclin B1 mRNA in the cell cycle and following irradiation in HeLa cells. EMBO J., 14, 603-609.
57. Datta, R., Hass, R., Gunji, H., Weichselbaum, R. and Kufe, D. (1992) Down-regulation of cell cycle control genes by ionizing radiation. Cell Growth Differ., 3, 637-644.
58. Waldmann, T., Lengauer, C., Kinzler, K.W. and Vogelstein, B. (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381, 713-716.
59. Buege, J.A. and Aust, S.D. (1978) Microsomal lipid peroxidation. Meth. Enzymol., 52, 302-310.
60. Morrow, J.D., Harris, T.M. and Roberts II, L.J. (1990) Noncylooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal. Biochem., 184, 1-10.
61. Eberhart, C.E., Coffey, R.J., Radhika, A., Giardiello, F.M., Ferrenbach, S. and DuBois, R.N. (1994) Up-regulation of cyclo-oxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-1188.
62. Kargman, S.L., O'Neill, G.P., Vickers, P.J., Evans, J.F., Mancini, J.A. and Jothy, S. (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55, 2556-2559.
63. Williams, C.S., Luonga, C., Radhika, A., Zhang, T., Lamps, L.W., Nanney, L.B., Beauchamp, R.D. and DuBois, R.N. (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 111, 1134-1140.
64. Liu, X.H. and Rose, D.P. (1996) Differential expression and regulation of cyclooxgenase-1 and -2 in two human breast cancer cell lines. Cancer Res., 56, 5125-5127.